These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 23523733)

  • 41. [Dosage adjustment of vancomycin in continuous infusion in critically ill-patients].
    Carricajo A; Forgeot A; Morel J; Auboyer C; Zeni F; Aubert G
    Ann Fr Anesth Reanim; 2010 Jan; 29(1):55-7. PubMed ID: 20074899
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis.
    Fernández de Gatta Mdel M; Santos Buelga D; Sánchez Navarro A; Dominguez-Gil A; García MJ
    Clin Pharmacokinet; 2009; 48(4):273-80. PubMed ID: 19492872
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties.
    Vandecasteele SJ; De Vriese AS; Tacconelli E
    J Antimicrob Chemother; 2013 Apr; 68(4):743-8. PubMed ID: 23249839
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Continuous infusion vancomycin for treatment of methicillin-resistant Staphylococcus aureus in cystic fibrosis patients.
    Fung L
    Ann Pharmacother; 2012 Oct; 46(10):e26. PubMed ID: 23032658
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
    Hidayat LK; Hsu DI; Quist R; Shriner KA; Wong-Beringer A
    Arch Intern Med; 2006 Oct; 166(19):2138-44. PubMed ID: 17060545
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus.
    Torrico M; Aguilar L; Sevillano D; Giménez MJ; Alou L; González N; Cafini F; Cleeland R; Prieto J
    Int J Antimicrob Agents; 2011 Apr; 37(4):332-8. PubMed ID: 21388792
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia.
    Suzuki Y; Kawasaki K; Sato Y; Tokimatsu I; Itoh H; Hiramatsu K; Takeyama M; Kadota J
    Chemotherapy; 2012; 58(4):308-12. PubMed ID: 23147106
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections.
    Hamada Y; Kuti JL; Nicolau DP
    J Antimicrob Chemother; 2015 Jul; 70(7):2064-7. PubMed ID: 25802284
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is vancomycin redundant for serious staphylococcal infection?
    Gould IM
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S55-7. PubMed ID: 21129922
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.
    Kitzis MD; Goldstein FW
    Clin Microbiol Infect; 2006 Jan; 12(1):92-5. PubMed ID: 16460555
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized controlled trial of a vancomycin loading dose in children.
    Demirjian A; Finkelstein Y; Nava-Ocampo A; Arnold A; Jones S; Monuteaux M; Sandora TJ; Patterson A; Harper MB
    Pediatr Infect Dis J; 2013 Nov; 32(11):1217-23. PubMed ID: 23817340
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [PK/PD of vancomycin in patients with severe acute pancreatitis combined with augmented renal clearance].
    He J; Mao E; Jing F; Jiang H; Xu W; Yang W; Chen E
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 Sep; 29(9):810-814. PubMed ID: 28936957
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations.
    Thomson AH; Staatz CE; Tobin CM; Gall M; Lovering AM
    J Antimicrob Chemother; 2009 May; 63(5):1050-7. PubMed ID: 19299472
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Determinants of early inadequate vancomycin concentrations during continuous infusion in septic patients.
    Ocampos-Martinez E; Penaccini L; Scolletta S; Abdelhadii A; Devigili A; Cianferoni S; de Backer D; Jacobs F; Cotton F; Vincent JL; Taccone FS
    Int J Antimicrob Agents; 2012 Apr; 39(4):332-7. PubMed ID: 22333933
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines.
    Kullar R; Leonard SN; Davis SL; Delgado G; Pogue JM; Wahby KA; Falcione B; Rybak MJ
    Pharmacotherapy; 2011 May; 31(5):441-8. PubMed ID: 21923425
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?
    Padari H; Oselin K; Tasa T; Metsvaht T; Lõivukene K; Lutsar I
    BMC Pediatr; 2016 Dec; 16(1):206. PubMed ID: 27931193
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Evaluation of pharmacodynamic target attainment with vancomycin treatment of bacteremia due to Staphylococcus aureus methicillin resistant].
    Lepe JA; Gil-Navarro MV; Santos-Rubio MD; Bautista J; Aznar J
    Rev Esp Quimioter; 2010 Mar; 23(1):43-7. PubMed ID: 20232023
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Continuous infusion vs intermittent vancomycin in neurosurgical intensive care unit patients.
    Hong LT; Goolsby TA; Sherman DS; Mueller SW; Reynolds P; Cava L; Neumann R; Kiser TH
    J Crit Care; 2015 Oct; 30(5):1153.e1-6. PubMed ID: 26239323
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
    De Jongh R; Hens R; Basma V; Mouton JW; Tulkens PM; Carryn S
    J Antimicrob Chemother; 2008 Feb; 61(2):382-8. PubMed ID: 18070831
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.